Apimeds Pharmaceuticals US Inc
APUS | AMEX
$2.93
-$0.07 (-2.50%)
Nov 2, 2026, 10:37 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 | Q4 2022 Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | -20.17M | -35.06M | -1.16M | -1.78M | -2.66M | -402.4K | -311.63K | -332.52K | -449.36K | -296.47K | -566.97K | -110.02K | -36.08K | -64.63K | -74.59K |
Depreciation & Amortization | 20.28K | 20.04K | 3.99K | 1.49K | 232 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | n/a | n/a | n/a | 42.67K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -1 | 22.44K | 47.55K | 48.39K |
Other Working Capital | 454.71K | 1.86M | -578.1K | 17.48K | -2.6M | 344.05K | 175.97K | 113.13K | 243.19K | 6.47K | 212.92K | -170.57K | -501 | n/a | -2.16K |
Other Non-Cash Items | 13.52M | 31.03M | -2.09M | -6.56K | 1.91M | 38.03K | 36.05K | 32.64K | 22.12K | 26.91K | 13.48K | 8.09K | 8.25K | 8.25K | 8.41K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 454.71K | 1.86M | -578.1K | 17.48K | -2.6M | 344.05K | 175.97K | 113.13K | 243.19K | 6.47K | 212.92K | -170.57K | -501 | n/a | -2.16K |
Operating Cash Flow | -6.18M | -2.14M | -3.82M | -1.73M | -3.36M | -20.31K | -99.62K | -186.76K | -184.06K | -263.1K | -340.57K | -272.5K | -5.89K | -8.83K | -19.96K |
Capital Expenditures | -4 | -9.39K | -21.43K | -22.54K | -13.36K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | -2M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | 1.5M | 500K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | -8M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | 1.5M | 490.61K | -10.02M | -22.54K | -13.37K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | 3.98M | 995K | 9.05M | n/a | n/a | 250K | n/a | 150K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 1K | n/a | -238.1K | n/a | -93.6K | 17.2K | 76.5K | n/a | 100K | n/a | -555K | 1.02M | n/a | 9K | 282.9K |
Financial Cash Flow | 3.98M | 995K | 8.49M | n/a | 11.86M | 267.2K | 76.5K | 150K | 100K | n/a | n/a | 1.02M | n/a | 9K | 282.9K |
Net Cash Flow | -701.16K | -657.12K | 2.65M | -1.75M | 8.48M | 246.89K | -23.12K | -36.76K | -84.06K | -263.1K | -340.57K | 750.6K | -5.89K | 171 | 262.95K |
Free Cash Flow | -6.18M | -2.15M | -3.84M | -1.75M | -3.37M | -20.31K | -99.62K | -186.76K | -184.06K | -263.1K | -340.57K | -272.5K | -5.89K | -8.83K | -19.96K |
Adj. Free Cash Flow | -6.18M | -2.15M | -3.84M | -1.79M | -3.37M | -20.31K | -99.62K | -186.76K | -184.06K | -263.1K | -340.57K | -272.5K | -28.33K | -56.38K | -68.34K |
Maintenance CapEx | -4 | -9.39K | -3.99K | -1.49K | -232 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Growth CapEx | n/a | n/a | -17.44K | -21.06K | -13.13K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Owner Earnings | -6.18M | -2.15M | -3.82M | -1.73M | -3.36M | -20.31K | -99.62K | -186.76K | -184.06K | -263.1K | -340.57K | -272.5K | -5.89K | -8.83K | -19.96K |
Add to Watchlist
Select watchlists to add or remove APUS